Racks Biotech

The move pressures global drugmakers and trading partners, with Switzerland singled out as exposed to the new US pricing and tariff posture.

Lilly's Zepbound and Mounjaro franchise continues to outpace its main rival in the duopoly that dominates obesity and diabetes care.

The Korean company says the four-hormone candidate outperformed rival triple-action drugs on weight loss and muscle preservation in animals, with global trials planned.

Strong anticoagulant and oncology sales offset post-COVID revenue declines as the company rebuilds growth.

A priority review sets up a potential first gene therapy approval in Huntington's disease, which company executives call a defining milestone.

Expanding the BTK inhibitor into front-line use broadens its label beyond relapsed disease in a competitive hematology market.

Manufacturing, litigation and contracting hurdles complicate the coming wave of biosimilar competition to Merck's blockbuster.

Experts welcomed the Indian drug pricing authority's move but said broader affordability and access concerns remain unaddressed.

The partial hold pauses parts of the study and clouds the timeline for the company's lead seizure candidate.

Investigators backing the Duchenne cardiomyopathy cell therapy are pressing regulators ahead of a decision on the candidate.

The company plans a prevention study, and separately reported lower bloodstream infection rates versus placebo in a transplant trial.

US pricing demands and tariff threats put Swiss pharmaceutical exports and industry pricing under scrutiny.

The voucher sale flattered quarterly results, illustrating how priority review vouchers have become a liquid asset for rare disease developers.

The rare disease specialist's quarterly update comes as it works to grow its hereditary angioedema franchise.

Dermatologic side effects can interrupt oncology treatment, so an effective topical option could help patients stay on therapy.

Local players including Epe are advancing GLP-1, muscle-building and patch therapies as competition in the category broadens.

The readout supports the pathogen-reduced blood product in a market where safety and supply reliability matter.

The call covers the company's progress in rare genetic obesity and hyperphagia treatments.

An overview of the company's brisk dealmaking and pipeline pruning as it concentrates resources on priority programs.

Investors and commentators are assessing how the weight-loss drug wave reshapes sectors beyond healthcare.

Relaxed registry requirements broaden real-world access to the pediatric kidney treatment.

The Korean drugmaker points to years of pipeline investment as it seeks to convert research into commercial revenue.

The finding highlights how cost containment continues to dominate employer decisions on prescription drug coverage.

An overview of the growing roster of obesity treatments entering or approaching the market.

Dividend-focused investors continue to look to large-cap pharma for steady payouts.